Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short-course therapy for tuberculosis.

M Aquinas

    Drugs
    |August 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Short-course tuberculosis therapy revolutionized treatment, but rifampicin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Melioidosis: a serological survey in a tuberculosis sanatorium in Hong Kong.

    Transactions of the Royal Society of Tropical Medicine and Hygiene·1987
    Same author

    Short-course chemotherapy.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1982
    Same author

    Metabolic support: how to form a service.

    Hospitals·1979
    Same author

    [Controlled trial of 6 to 8 month chemotherapeutic regimens in the treatment of pulmonary tuberculosis. A study of Hong Kong Chest Service/British Medical Research Council/].

    Bulletin of the International Union against Tuberculosis·1978
    Same author

    Drug treatment of pulmonary tuberculosis.

    Drugs·1975
    Same author

    Chemotherapy and practical delivery of treatment programmes.

    Bulletin of the International Union against Tuberculosis·1974
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    Same journal

    Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

    Drugs·2026
    Same journal

    Linerixibat: First Approval.

    Drugs·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Public Health

    Background:

    • Rifampicin discovery enabled 6-month tuberculosis treatment, replacing 18-24 month regimens.
    • High cost of rifampicin limits its accessibility in low-income, high-tuberculosis prevalence countries.
    • Pyrazinamide has been re-evaluated and is crucial in combination therapy for short-course chemotherapy.

    Purpose of the Study:

    • To evaluate the efficacy and safety of short-course tuberculosis chemotherapy regimens.
    • To determine optimal drug combinations and durations for tuberculosis treatment.
    • To assess the impact of drug regimens on relapse rates and adverse reactions.

    Main Methods:

    • Review of existing studies on short-course tuberculosis chemotherapy.
    • Analysis of drug combinations, dosages, and administration schedules.

    Related Experiment Videos

  • Evaluation of relapse rates and adverse event incidence in various treatment regimens.

    • Main Results:

    • Rifampicin is vital for effective short-course tuberculosis therapy.
    • Pyrazinamide's efficacy is primarily in the initial 2 months; prolonged use is unnecessary.
    • Regimens including isoniazid, rifampicin, and pyrazinamide are essential for a 6-month duration.
    • Treatment shorter than 6 months for smear-positive tuberculosis leads to unacceptable relapse rates.

    Conclusions:

    • A 6-month regimen combining isoniazid, rifampicin, and pyrazinamide is essential for effective tuberculosis treatment.
    • Curtailing treatment duration below 6 months increases relapse rates.
    • Ongoing research aims to optimize tuberculosis treatment for simplicity, efficacy, safety, and cost-effectiveness.